{"preliminary_commentary":{"by_channel":{"x_thread":4,"podcast":3,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00861705\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"CALGB 40603","nct_id":"NCT00861705","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=calgb-40603-nct00861705. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive paclitaxel IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19.","label":"Arm I (paclitaxel, doxorubicin, cyclophosphamide)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive paclitaxel and ddAC as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17.","label":"Arm II (paclitaxel, ddAC, bevacizumab)","type":"EXPERIMENTAL"},{"description":"Patients receive paclitaxel and ddAC as in Arm I. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10.","label":"Arm III (paclitaxel, ddAC, carboplatin)","type":"EXPERIMENTAL"},{"description":"Patients receive paclitaxel and ddAC as in Arm I, bevacizumab as in Arm II, and carboplatin as in Arm III.","label":"Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-09-02","type":"ACTUAL"},"conditions":["Male Breast Carcinoma","Stage IIA Breast Cancer AJCC v6 and v7","Stage IIB Breast Cancer AJCC v6 and v7","Stage IIIA Breast Cancer AJCC v7","Triple-Negative Breast Carcinoma"],"enrollment":{"count":454,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Bevacizumab","otherNames":["ABP 215","ABP-215","ABP215","Alymsys","Anti-VEGF","Anti-VEGF Humanized Monoclonal Antibody","Anti-VEGF Monoclonal Antibody SIBP04","Anti-VEGF rhuMAb","Avastin","Avzivi","Aybintio","BAT 1706","BAT-1706","BAT1706","BAT1706 Biosimilar","Bevacizumab awwb","Bevacizumab Biosimilar ABP 215","Bevacizumab Biosimilar BAT1706","Bevacizumab Biosimilar BEVZ92","Bevacizumab Biosimilar BI 695502","Bevacizumab Biosimilar CBT 124","Bevacizumab Biosimilar CT-P16","Bevacizumab Biosimilar FKB238","Bevacizumab Biosimilar GB-222","Bevacizumab Biosimilar HD204","Bevacizumab Biosimilar HLX04","Bevacizumab Biosimilar IBI305","Bevacizumab Biosimilar LY01008","Bevacizumab Biosimilar MB02","Bevacizumab Biosimilar MIL60","Bevacizumab Biosimilar Mvasi","Bevacizumab Biosimilar MYL-1402O","Bevacizumab Biosimilar QL 1101","Bevacizumab Biosimilar QL1101","Bevacizumab Biosimilar RPH-001","Bevacizumab Biosimilar SCT501","Bevacizumab Biosimilar Zirabev","Bevacizumab-adcd","Bevacizumab-awwb","Bevacizumab-aybi","Bevacizumab-bvzr","Bevacizumab-equi","Bevacizumab-maly","Bevacizumab-onbe","Bevacizumab-tnjn","BP102","BP102 Biosimilar","CT P16","CT-P16","CTP16","Equidacent","FKB 238","FKB-238","FKB238","HD204","Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer","MB 02","MB-02","MB02","Mvasi","MYL-1402O","Onbevzi","Oyavas","PF 06439535","PF-06439535","PF06439535","QL1101","Recombinant Humanized Anti-VEGF Monoclonal Antibody","rhuMab-VEGF","SCT501","SIBP 04","SIBP-04","SIBP04","Vegzelma","Zirabev"],"type":"BIOLOGICAL"},{"name":"Carboplatin","otherNames":["Blastocarb","Carboplat","Carboplatin Hexal","Carboplatino","Carboplatinum","Carbosin","Carbosol","Carbotec","CBDCA","Displata","Ercar","JM-8","JM8","Nealorin","Novoplatinum","Paraplatin","Paraplatin AQ","Paraplatine","Platinwas","Ribocarbo"],"type":"DRUG"},{"name":"Cyclophosphamide","otherNames":["(-)-Cyclophosphamide","2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate","Asta B 518","B 518","B-518","B518","Carloxan","Ciclofosfamida","Ciclofosfamide","Cicloxal","Clafen","Claphene","CP monohydrate","CTX","CYCLO-cell","Cycloblastin","Cycloblastine","Cyclophospham","Cyclophosphamid monohydrate","Cyclophosphamide Monohydrate","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphanum","Cyclostin","Cyclostine","Cytophosphan","Cytophosphane","Cytoxan","Fosfaseron","Genoxal","Genuxal","Ledoxina","Mitoxan","Neosar","Revimmune","Syklofosfamid","WR 138719","WR- 138719","WR-138719","WR138719"],"type":"DRUG"},{"name":"Doxorubicin Hydrochloride","otherNames":["5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)","ADM","Adriacin","Adriamycin","Adriamycin Hydrochloride","Adriamycin PFS","Adriamycin RDF","ADRIAMYCIN, HYDROCHLORIDE","Adriamycine","Adriblastina","Adriblastine","Adrimedac","Chloridrato de Doxorrubicina","DOX","DOXO-CELL","Doxolem","Doxorubicin HCl","Doxorubicin.HCl","Doxorubin","Farmiblastina","FI 106","FI-106","FI106","hydroxydaunorubicin","Rubex"],"type":"DRUG"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"},{"name":"Paclitaxel","otherNames":["Anzatax","Asotax","Bristaxol","Praxel","Taxol","Taxol Konzentrat"],"type":"DRUG"}],"last_update":"2026-06-29","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2014-08-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Pathologic Complete Response (pCR) in the Breast. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is).","timeFrame":"At the time of definitive surgical removal, up to 28 weeks"},{"measure":"Pathologic Complete Response (pCR) in the Breast. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is).","timeFrame":"At the time of definitive surgical removal, up to 28 weeks"}],"references":[{"citation":"Radler PD, Felsheim BM, Fernandez-Martinez A, Pfefferle AD, Hayward MC, Singh B, Sikov W, Carey LA, Perou CM. Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple negative breast cancer CALGB40603 (Alliance). J Clin Invest. 2026 Aug 4:e205962. doi: 10.1172/JCI205962. Online ahead of print.","pmid":"42550611","type":"DERIVED"},{"citation":"Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Hudis CA, Winer EP, Partridge A, Hyslop T, Carey LA, Perou CM, Sikov WM. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022 Apr 20;40(12):1323-1334. doi: 10.1200/JCO.21.01506. Epub 2022 Jan 19.","pmid":"35044810","type":"DERIVED"},{"citation":"Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4.","pmid":"25092775","type":"DERIVED"}],"start_date":{"date":"2009-07-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery","url":"https://clinicaltrials.gov/study/NCT00861705"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/calgb-40603-nct00861705"}